Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC
OncologiaSobre o estudo
- Desenho
- Diretriz clínica
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- The French journal of urology
- Publicado em
- 26 jun 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC
Priscilla Leon, Thibaut Long-Depaquit, François Audenet, Yves Allory, Alexandra Masson-Lecomte, Benjamin Pradère, Thomas Seisen, Evanguelos Xylinas, Marcq Gautier, Constance Thibault et al.
Descritores MeSH
- Non-Muscle Invasive Bladder Neoplasms
- Antibiotics, Antineoplastic
- BCG Vaccine
- Urinary Bladder Neoplasms
- Epirubicin
- Mitomycin
- Administration, Intravesical
- Humans
- Societies, Medical
- Urology
Veja também
Estudos relacionados
- A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer
- Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)
- A randomized study comparing outcomes of intravesical Gemcitabine, Mitomycin C (as hyperthermic intravesical chemotherapy-HIVEC) and Bacillus-Calmette Guerin in intermediate and high-risk non-muscle invasive bladder cancer
- A 3-arm randomized control trial to compare the efficacy of re-circulant hyperthermic intravesical chemotherapy versus conventional intravesical mitomycin C and BCG therapy for intermediate-risk non-muscle invasive bladder cancer